Ophthalmic compositions and ophthalmic lenses having multiple comonomer groups

Abstract

This invention relates to an ophthalmic composition for the production of an ophthalmic lens (10), the ophthalmic composition comprising comonomer groups A) to C), at least one of comonomer groups D), E), or mixtures thereof, and at least one crosslinking agent F). Here: A) represents at least one (meth)acrylate having at least one aromatic group; B) represents at least one (meth)acrylate having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; C) represents at least one (meth)acrylate having at least one hydroxyl group; D) represents at least one (meth)acrylamide having an aromatic group and having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; and E) represents at least one (meth)acrylamide having two aromatic groups and at least one (meth)acrylamide having two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups. Each of these comonomer groups comprises components determined based on the total weight of the ophthalmic composition. The invention also relates to an ophthalmic lens (10) produced at least in part from this ophthalmic composition.

Description

Technical Field

[0001] The present invention relates to an ophthalmic composition having two or more comonomer groups, and to an ophthalmic lens, particularly a soft intraocular lens, which is produced at least in part from such an ophthalmic composition. Existing technology

[0002] In recent decades, a wide variety of biomaterials suitable for the production of ophthalmic compositions and lenses, especially intraocular lenses (IOLs), have been developed. Different categories of materials include hydrophilic polymers, hydrophobic polymers, and silicone. Each category has its own advantages and disadvantages. Although silicone IOLs exhibit very good resistance to posterior cataract (PCO), their post-injection spread behavior can be uncontrollable. Hydrophilic lenses generally show very good biocompatibility but also exhibit higher PCO and calcification rates. In recent years, hydrophobic IOLs have seen the fastest growth. They typically... D It offers a relatively high refractive index in the range of 1.44-1.55, but carries the risk of "flare," characterized by aqueous microvacuoles that form within the polymer matrix and can potentially impair a patient's visual perception, especially when using multifocal lenses. Vacuoles up to 120 μm below the IOL surface with a diameter of less than 200 nm are also known as "nanoflares" (subsurface nanoflares, SSNG).

[0003] US2002 / 0049290 A1 discloses optically transparent hydrogels with high refractive indexes and intraocular lenses made therefrom. Preferred hydrogels have a refractive index of 1.45 or higher and a water content of about 5 to 30 percent by weight.

[0004] WO 99 / 58507A1 discloses hydrophilic, UV-absorbing polymeric monomers. These monomers are copolymerizable and produce biocompatible hydrogels that can absorb at least 90% of the UV light incident on the hydrogel. Such hydrogels are optically transparent, have a high refractive index, and exhibit long-term stability.

[0005] US2013 / 0231740 A1 discloses relatively soft, optically transparent, foldable materials with high refractive indexes, which are particularly suitable for use in the manufacture of artificial lenses, contact lenses, and other eye implants.

[0006] To tailor materials for specific applications such as ophthalmic lenses, complex multi-parameter optimization is necessary. In addition to ensuring biocompatibility, optical, physical, and mechanical properties must be optimized simultaneously. For example, a material with excellent biocompatibility but low flexibility is not ideal, as this would result in a larger incision for IOL implantation. This is particularly important because the goal is to minimize incisions (micro-incision cataract surgery, MICS with incisions <2 mm). The choice of matrix material is especially crucial here. Hydrophobic polymers inherently offer good matrix properties for developing MICS-compatible materials, namely a combination of high tensile strength and high refractive index. However, anti-glow and material flexibility must be significantly improved. A new class of materials, called "new hydrophobic acrylates," is the result of recent research in the field of IOL materials. Table 1 below provides an overview of the current standard material categories.

[0007] Table 1: Physical Properties of Standard IOL Materials

[0008]

[0009] "Hyg." indicates the mass percentage of water in the lens at equilibrium at 35°C, "contact angle" is the angle between the leading edge of the water droplet and the surface of the material, "tensile strength" is the maximum stress that a material type can withstand when stretched without breaking, "refractive index n" indicates the refractive index at 20°C, and "Tg" indicates the glass transition temperature.

[0010] Hydrophilic materials typically have low refractive indices, which actually decrease further when fully hydrated. Therefore, the lens curvature and thickness must necessarily be significantly greater at high refractive powers compared to materials with higher refractive indices. This necessitates implanting a large lens cross-section through a small injection tip, increasing the risk of damage to the cartridge tip of the implantation tool or the lens itself. In the case of these materials, greater material flexibility can be achieved through high water absorption rates of 5 to 30 percent. However, this not only significantly reduces the refractive index but also necessitates storing the lens in an aqueous or at least moisture-controlled package. Otherwise, it is impossible to ensure dimensional accuracy and optical quality after lens implantation.

[0011] The main idea behind the "new hydrophobic acrylate" is to add the hydrophilic monomer HEMA (2-hydroxyethyl methacrylate) to the originally hydrophobic comonomer, as this has the ability to disperse water throughout the material. Known ophthalmic compositions contain approximately 30% HEMA to prevent flaking, and approximately 4% by weight of equilibrium water. Due to the latter proportion, the corresponding IOLs must be stored in a 0.9% saline solution and are therefore unsuitable for dry pre-loaded IOL implantation systems.

[0012] In some cases of "new hydrophobic acrylates," the risk of sparking is said to be reduced, but with a relatively low refractive index n d The trade-off is a cost of less than 1.5. This means that, as already mentioned, the cross-section of the lens, and therefore the required cutting size, must be significantly increased according to the refractive power. Furthermore, these materials exhibit a relatively slow lens unfolding speed under simulated operating conditions (26°C water bath) and are unsuitable for steam sterilization, severely limiting the choice of sterilization procedures, which are mandatory for ophthalmic implants.

[0013] Therefore, recent developments in the field of IOL biomaterials point to interesting directions for further development, but improvements are still needed for implants that provide faster and less invasive surgery combined with higher patient satisfaction. Summary of the Invention

[0014] Therefore, an object of the present invention is to provide an ophthalmic composition that enables the production of flexible, biocompatible ophthalmic lenses with a high refractive index and a minimal risk of flicker, wherein the ophthalmic lenses produced by the composition are dry-storeable and sterilizable by steam sterilization. Another object of the present invention is to indicate a corresponding ophthalmic lens.

[0015] These objectives are achieved according to the invention by an ophthalmic composition having the features of claim 1 and an ophthalmic lens according to claim 6. Advantageous configurations having suitable developments of the invention are indicated in the corresponding dependent claims; advantageous configurations of the ophthalmic composition should be considered as advantageous configurations of the ophthalmic lens, and vice versa.

[0016] A first aspect of the invention relates to an ophthalmic composition for producing an ophthalmic lens, the ophthalmic composition comprising a comonomer group A) to C), at least one of a comonomer group D), E), or a mixture thereof, and at least one crosslinking agent F). In this context, A) represents at least one (meth)acrylate having at least one aromatic group; B) represents at least one (meth)acrylate having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; C) represents at least one (meth)acrylate having at least one hydroxyl group; D) represents at least one (meth)acrylamide having an aromatic group and having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; and E) represents at least one (meth)acrylamide having two aromatic groups and at least one (meth)acrylamide having two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups. In other words, according to the present invention, the ophthalmic composition is envisioned to comprise monomers from at least four or five different molecular classes A), B), C), D), or A), B), C), E), or A), B), C), D), E), and at least one crosslinking agent F), or in its simplest form composed of the mentioned molecular classes and free of any other molecular classes. The compositions of the present invention are preferably free of silicon and / or siloxanes and preferably free of fluorinated compounds. Molecular classes A) through E) act as comonomers in the polymer synthesized from the ophthalmic compositions of the present invention and can be crosslinked by means of crosslinking agent F). Therefore, the compositions of the present invention may also be referred to as prepolymers. In the context of this disclosure, without any explicit discussion of specific individual compounds, the term "(meth)acrylate" is always used to refer to acrylates, methacrylates, and any mixtures thereof. For example, the expression "(meth)acrylate 2-phenylethyl ester" covers the compounds 2-phenylethyl acrylate, 2-phenylethyl methacrylate, and any mixture of these two compounds. The same applies to the expression "(meth)acrylamide," which, without any explicit discussion of specific individual compounds, always covers acrylamide, methacrylamide, or mixtures thereof. In the context of this disclosure, “a / an” should generally be understood as an indefinite article, meaning that it is always understood as “at least one” unless there is an explicit indication to the contrary. Conversely, “a / an” can also be understood as “only one”.

[0017] The ophthalmic compositions of the present invention are particularly suitable for the production of soft, MICS-compatible intraocular lenses, but in principle, they can also be used for the production of other ophthalmic lenses, implants, artificial corneas, inlays, etc. Simultaneously, the compositions of the present invention enable the production of ophthalmic lenses that offer high patient satisfaction due to their very low scintillation tendency. Implantation surgery can be further improved by the rapid, controlled deployment speed of lenses made from this composition. The ophthalmic compositions of the present invention also allow for the production of ophthalmic lenses that can be used in fully pre-loaded syringe systems with both dry and wet storage. This reduces manufacturing complexity and facilitates storage while maintaining complete design freedom. Finally, the ophthalmic compositions of the present invention, or lenses produced therefrom, can be sterilized by steam sterilization. This not only opens up a wider range of manufacturing processes compared to the established ethylene oxide (EtO) sterilization of standard hydrophobic IOLs, but also utilizes a more sustainable and cost-effective method.

[0018] This invention is based on the discovery that, in order to design polymeric biomaterials that combine all the above requirements (if possible), it is required to be an ophthalmic composition containing at least four different classes of monomers or comonomers, each monomer or comonomer having different properties.

[0019] Group A) can also be referred to as "aromatic monomers," which contain at least one aromatic group or aryl ring to increase the refractive index of the resulting polymer. The term "aryl ring" includes both individual rings (e.g., phenyl) and fused and separated aromatic ring systems (e.g., naphthyl or biphenyl rings). Each aryl ring may carry one or more substituents. The aryl rings are preferably selected from C... 6-18 -Aryl.

[0020] Group B) comprises monomers having aliphatic groups, which can be used to increase the flexibility of the material. Alternatively, or in addition to open-chain aliphatic groups, one or more non-aromatic cyclic groups, such as cyclohexyl, and / or one or more non-aromatic heterocyclic groups, such as piperidinyl, may be provided. The aliphatic groups are preferably selected from C. 1-12 -alkyl groups, which are preferably unbranched or -as branched as possible. Heterocyclic groups preferably have at least one atom from the group consisting of N, S and / or O and are suitable for forming hydrogen bonds. Aliphatic groups are preferably straight-chain, but in principle they may also be branched. In addition, each aliphatic non-aromatic cyclic or non-aromatic heterocyclic group may also contain one or more carbon double and / or triple bonds.

[0021] Group C) contains one or more monomers having at least one hydroxyl group. These are preferably one or more terminal or spatially unhindered hydroxyl groups, which are capable of forming hydrogen bonds in the polymer. Group C) is added primarily to increase the water absorption of the polymer composition.

[0022] Group D) contains “mixed” (meth)acrylamide comonomers, which lead to unexpected improvements in the properties of the resulting biomaterials. Molecular category D), defined herein as “mixed” (meth)acrylamide comonomers, contains vinyl functional groups and tertiary amides for polymerization. The advantage of using acrylamide over acrylates is that each monomer unit can be attached to two terminal substituents. In the case of “mixed” acrylamide, the two substituents or functional groups in group D) are different. The comonomers of group D) therefore have the general formula (I).

[0023]

[0024] Where R 1 =H / CH3, R 2 = A group containing an aryl group and R 3 = alkyl, where R 2 and / or R 3 Preferably, it is unsubstituted. Two substituents R are selected. 2 and R 3 This makes it preferable that they have the same or very similar chemical structures as those of the aromatic monomers A) or aliphatic monomers B) used in the ophthalmic compositions discussed. Therefore, generally, the same considerations and limitations as those for the substituents of the comonomers of groups A) and B) apply to the substituents of the comonomers of group D). These structural similarities lead to favorable intermolecular interactions between the different comonomer groups A), B), and D) in the latter polymer, as acrylamide D) acts as a mediator between groups A) and B). The aryl group of acrylamide D) also advantageously leads to an increase in refractive index and forms π-π interactions with the molecules of aromatic monomer A), resulting in higher structural strength of the polymer. The alkyl group of acrylamide D) can increase the flexibility of the material, or, in the case of branched or cyclic / heterocyclic substituents, provide higher lightfastness and tear resistance. In some embodiments, R in formula (I) 3 Alternatively, it can be specifically substituted with one or more hydroxyl groups. In this way, comonomer D) may be structurally similar to comonomer C), and therefore it is correspondingly possible to develop favorable intermolecular interactions among groups A), C) and D).

[0025] Alternatively, or in addition to group D), group E may also be used. Therefore, both groups D) and E) are used synonymously below. Group E) comprises a mixture of at least two different (meth)acrylamides, wherein the first (meth)acrylamide has two aromatic groups and the second (meth)acrylamide has two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups. In other words, group E) comprises two molecular classes of general formulas IIa and IIb:

[0026]

[0027] In equation IIa, R 1 =H / CH3 and R 2 and R 3 = A group containing an aryl group, and in formula IIb, R 1 =H / CH3 and R 2 and R 3 = alkyl, where R 2 and R 3 Independently, they are unsubstituted and / or particularly substituted with one or more hydroxyl groups in order to interact with the comonomers of group C). Therefore, the two substituents R of (meth)acrylamide 2 R 3 They can be the same or different. Otherwise, the same considerations and limitations as for the substituents in groups A), B), and C) apply to the substituents in group E). Compared to group D), group E) therefore does not cover intramolecular “mixed” (meth)acrylamides, but rather a “mixed” mixture of at least two different (meth)acrylamides, wherein mixture E) can also act as a medium between group A) and B) or C) in the polymer. Compared to the mixed compounds of group D), some individual compounds of group E) can be synthesized more easily and at a lower cost, especially when the individual (meth)acrylamides each carry two identical substituents R. 2 R 3 hour.

[0028] To produce a biocompatible elastomer suitable for use as a soft IOL, and preferably not thermoplastic, at least one crosslinking agent (F) is provided. This crosslinking agent is designed to generate covalent bonds between polymer chains, which ensure reliable unfolding and provide a balance between material thickness and flexibility. Two or more different crosslinking agents can also be provided to specifically tune the mechanical properties of the polymer.

[0029] Because polymer chains typically contain denser regions and other more loosely folded regions, the lower-density regions can cause localized water accumulation, especially when environmental conditions change rapidly (e.g., in the event of a sudden temperature change). Therefore, the present invention is also based on the finding that this risk can be significantly reduced by using flexible substituents that can be freely oriented. This is particularly true for unsubstituted or substituted alkyl groups provided or available in comonomer groups B), C), D), and E).

[0030] On the other hand, it has been recognized that it is important to use hydrophilic or hygroscopic comonomers that are distributed with maximum uniformity in the polymer matrix. These comonomers according to group C) not only locally stabilize water by forming hydrogen bonds, but also form non-covalent bonds with the functional groups of amides (group D) / E), which leads to higher structural strength of the polymer.

[0031] According to the present invention, based on the total weight of the ophthalmic composition, the proportion of comonomer group A) is between 30% and 60% by weight, and therefore is, for example, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, etc. by weight. 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight, 48% by weight, 49% by weight, 50% by weight, 51% by weight, 52% by weight, 53% by weight, 54% by weight, 55% by weight, 56% by weight, 57% by weight, 58% by weight, 59% by weight, or 60% by weight. The proportion of comonomer group B) is between 10% and 45% by weight, and therefore, for example, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, and 25% by weight. %, 26% by weight, 27% by weight, 28% by weight, 29% by weight, 30% by weight, 31% by weight, 32% by weight, 33% by weight, 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, or 45% by weight. The proportion of comonomer group C) is between 5% and 30% by weight, and is therefore, for example, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 21% by weight, 22% by weight, 23% by weight, 24% by weight, 25% by weight, 26% by weight, 27% by weight, 28% by weight, 29% by weight, or 30% by weight.The total percentage of comonomer groups D) and E) is between 1% and 14% by weight, and is therefore, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, or 14% by weight. The proportion of crosslinking agent F) is no more than 5% by weight, and therefore is, for example, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, and 2.3% by weight. The crosslinking agent (F) is preferably between 2.4% and 5.0% by weight. The crosslinking agent (F) is also available in the following proportions: 2.4% by weight, 2.5% by weight, 2.6% by weight, 2.7% by weight, 2.8% by weight, 2.9% by weight, 3.0% by weight, 3.1% by weight, 3.2% by weight, 3.3% by weight, 3.4% by weight, 3.5% by weight, 3.6% by weight, 3.7% by weight, 3.8% by weight, 3.9% by weight, 4.0% by weight, 4.1% by weight, 4.2% by weight, 4.3% by weight, 4.4% by weight, 4.5% by weight, 4.6% by weight, 4.7% by weight, 4.8% by weight, 4.9% by weight, or 5.0% by weight.

[0032] (Methacrylamide comonomers D) / E) are preferably used as an "additive" in the ophthalmic composition. This means that the sum of (meth)acrylamide D) / E) in weight percent is preferably minimal compared to the remaining comonomer types A) to C) in the composition. It will be understood that the proportions of all components in the ophthalmic composition are always and uniquely totaled as 100% by weight. Generally, unless otherwise stated, percentages in the context of this disclosure should be considered as mass percentages.

[0033] In an advantageous configuration of the invention, comonomer group A) comprises 2-phenylethyl acrylate, 2-phenylethyl methacrylate, ethylene glycol phenyl ether acrylate, ethylene glycol phenyl ether methacrylate, or mixtures thereof. Alternatively or additionally, comonomer group B) comprises butyl acrylate, butyl methacrylate, isobutyl acrylate, isobutyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, or mixtures thereof. Alternatively or additionally, comonomer group C) comprises 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate, 4-hydroxybutyl acrylate, 4-hydroxybutyl methacrylate, or mixtures thereof. Alternatively or additionally, comonomer group D) may include or contain N-benzyl-N-isopropylacrylamide, N-benzyl-N-isopropylmethacrylamide, N-benzyl-N-butylacrylamide, N-benzyl-N-butylmethacrylamide, N-benzyl-N-isobutylacrylamide, N-benzyl-N-isobutylmethacrylamide, N-benzyl-N-isopentylacrylamide, N-benzyl-N-isopentylacrylamide, N-benzyl-N-pentylmethacrylamide, N-benzyl-N-methylacrylamide, N-benzyl-N-methylmethacrylamide, N-benzyl-N-methylmethacrylamide, or mixtures thereof. Alternatively or additionally, comonomer group E) comprises N,N-dibenzyl (meth)acrylamide and N,N-diisopropyl (meth)acrylamide, N,N-dibenzyl (meth)acrylamide and N,N-dibutyl (meth)acrylamide, N,N-dibenzyl (meth)acrylamide and N,N-diisobutyl (meth)acrylamide, N,N-dibenzyl (meth)acrylamide, N,N-diisopentyl (meth)acrylamide and N,N-dipentyl (meth)acrylamide, N,N-dibenzyl (meth)acrylamide and N,N-dimethyl (meth)acrylamide, or mixtures thereof. Alternatively or additionally, F) comprises or has a crosslinking agent having at least two acrylate groups, at least two methacrylate groups, or at least one acrylate and at least one methacrylate group, wherein the crosslinking agent particularly comprises or has butanediol diacrylate and / or ethylene glycol dimethacrylate. This ophthalmic composition is particularly suitable for the production of transparent ophthalmic biomaterials having a favorable refractive index n of about 1.50 or greater in the hydrated state. D,35 ℃, Shore A hardness less than 80 (t=3s) or less than 50 (t=10min), glass transition temperature between 0℃ and 15℃, water absorption capacity at 35℃ between 0.5% and 3.5% by weight, and an Abbe number of at least 30.

[0034] Regarding Shore A hardness values, it should be noted that these can be determined at different indentation times t within the scope of this disclosure. Each indentation time t is included within the scope of this disclosure. Typically, measurements for elastomers (e.g., rubber) are performed after 3 seconds, as defined in DIN ISO 7619-1. The Shore A limit for the materials of the present invention conforming to DIN is preferably a maximum of 80 or less (t = 3 s), preferably a maximum of 65 or less (t = 3 s). Alternatively or additionally, at an indentation time t = 10 min, the Shore A value is at most 50 or less.

[0035] Another advantage is that the ophthalmic composition contains at least one additional component G), H), I), or a mixture thereof, wherein G) represents at least one preferably covalently bonded UV absorber, H) represents at least one preferably covalently bonded dye for modifying light absorption properties, and I) represents a polymerization initiator. With the aid of component G), UV absorption properties are preferably provided in at least the wavelength range between about 300 nm and about 400 nm. With the aid of component H) (which may also be referred to as a yellow dye), the ophthalmic composition can be readily adapted to provide yellow biomaterials for the production of lenses having, for example, maximum absorption in the wavelength range between about 400 nm and about 500 nm. The amount of yellow dye used in the composition can be selected within a relatively wide concentration range as needed to obtain the desired percentage of transmittance at each wavelength in the range between about 400 nm and about 500 nm. It is also possible to achieve the desired absorption properties of the biomaterial or lens produced therefrom in the human visible wavelength range by one or more of components G) and / or H) (preferably covalently bonded in the reacting polymer to avoid external diffusion). With the aid of a polymerization initiator, it is possible to modulate the nature and rate of the polymerization reaction of this ophthalmic composition.

[0036] Further advantages regarding the various properties of the ophthalmic composition and the biomaterials formed therefrom arise from the following: based on the total weight of the ophthalmic composition, the proportion of component G) does not exceed 2% by weight, i.e., for example, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, or 2.0% by weight, especially... It is not more than 1% by weight, and / or the proportion of component H) is not more than 5% by weight, i.e., for example, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, and 2.4% by weight. %, 2.5% by weight, 2.6% by weight, 2.7% by weight, 2.8% by weight, 2.9% by weight, 3.0% by weight, 3.1% by weight, 3.2% by weight, 3.3% by weight, 3.4% by weight, 3.5% by weight, 3.6% by weight, 3.7% by weight, 3.8% by weight, 3.9% by weight, 4.0% by weight, 4.1% by weight, 4.2% by weight, 4.3% by weight, 4.4% by weight, 4.5% by weight, 4.6% by weight, 4.7% by weight, 4.8% by weight, 4.9% by weight, or 5.0% by weight, and / or the proportion of component I) by weight. The percentage shall not exceed 3%, for example, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1.0% by weight, 1.1% by weight, 1.2% by weight, 1.3% by weight, 1.4% by weight, 1.5% by weight, 1.6% by weight, 1.7% by weight, 1.8% by weight, 1.9% by weight, 2.0% by weight, 2.1% by weight, 2.2% by weight, 2.3% by weight, 2.4% by weight, 2.5% by weight, 2.6% by weight, and 2.5% by weight.7%, 2.8% by weight, 2.9% by weight, or 3.0% by weight.

[0037] It has also been found advantageous when the UV absorber (G) is 2-(5-chloro-2H-benzotriazol-2-yl)-6-(1,1-dimethylethyl)-4-vinylphenol (UVAM). Alternatively or additionally, it has been found advantageous when the dye (H) is the yellow dye 4-(3-vinylphenylazo)diphenylamine (3VPADPA or VPAD). Because the yellow dye absorbs in the range between 400 nm and 500 nm, it is also known as a "blue light absorber." These compounds, alone or in any combination, allow the production of biomaterials with absorption properties particularly advantageous for the ophthalmic lens in the wavelength range between about 300 nm and 400 nm (G) or between about 400 nm and about 500 nm (H). In other words, the combination of UV and blue light absorbers (G) and (H) can be used to adjust the absorption properties within a specified wavelength range as needed. In this way, the level of high-energy blue light is reduced. If no blue light absorber (H) is added and only a UV absorber (G) is used, the absorption cutoff value is preferably set at about 400 nm and the biomaterial of the present invention remains colorless, providing maximum UV protection.

[0038] A second aspect of the invention relates to an ophthalmic lens made at least in part from an ophthalmic composition according to a first aspect of the invention. This ophthalmic lens is particularly a soft intraocular lens. In certain embodiments, the lens may have an optical portion and a tactile portion. The lens may also be composed of two or more different biomaterials, wherein at least one biomaterial is according to the invention. The entire lens is preferably produced from one or more compositions of the invention or the biomaterials of the invention. Thus, in some embodiments, the lens may have two or more regions with different optical, physical, and / or mechanical properties. However, it is also possible that the ophthalmic lens is designed as a contact lens. By using an ophthalmic composition according to a first aspect of the invention to achieve the ophthalmic lens according to the invention, the lens of the invention is flexible, biocompatible, and has a high refractive index and a particularly low risk of flicker under physiological conditions. Furthermore, the ophthalmic lens can be stored dry and sterilized by steam sterilization. Further resulting features and advantages can be inferred from the description of the first aspect of the invention; advantageous embodiments of the first aspect of the invention should be considered advantageous embodiments of the second aspect of the invention, and vice versa.

[0039] In an advantageous configuration of the invention, the ophthalmic lens in its dehydrated state has a refractive index n. D,20 ℃>1.51 and / or having a refractive index n in the hydrated state D,35The ophthalmic lens of the present invention possesses a Shore A hardness >1.50 °C and / or less than 80 (t=3s), particularly not greater than 65 (t=3s), or less than 50 (t=10min), and / or a glass transition temperature between 0 °C and 15 °C, particularly between 4 °C and 9 °C, and / or a water absorption capacity at 35 °C between 0.5% and 3.5% by weight, particularly between 1.5% and 2.5% by weight, and / or an Abbe number of at least 30, preferably at least 40. In this way, the ophthalmic lens of the present invention combines one or more particularly advantageous properties. The ophthalmic lens preferably satisfies all of the above-described properties.

[0040] In another advantageous configuration of the invention, in an in vitro scintillation test performed by accelerated aging, wherein the lens is first placed in a saline solution at 45°C ± 1°C for 24 hours and then at 37°C ± 1°C for 2.5 hours, the ophthalmic lens exhibits a strength not exceeding 10 MVs / mm. 2 Preferably not exceeding 1MVs / mm 2 The microvacuolar density is high. In other words, the ophthalmic lens advantageously has a particularly low microvacuolar density, which is determined by the referenced test method. The saline solution is preferably a physiological saline solution (NaCl concentration 9 g / L, osmotic pressure 308 mOsm / L). In this way, problems otherwise caused by glare, such as glare symptoms when there is oncoming light at night or when driving on a sunny day, are completely or at least substantially completely avoided. More preferably, the lens is glare-free and, in particular, microvacuolar-free, as this can be achieved without difficulty using the ophthalmic composition of the present invention.

[0041] In another advantageous embodiment of the invention, the ophthalmic lens has been steam-sterilized. In this way, the lens of the invention can be inexpensively sterilized by a predetermined steam sterilization process, which advantageously eliminates the need for chemical sterilization methods. Alternatively or additionally, the ophthalmic lens has been plasma-treated. This can advantageously reduce surface stickiness. For example, plasma treatment can be carried out in a furnace equipped with an HF plasma generator (e.g., 13.56 MHz) and in a mixed atmosphere of oxygen and argon (e.g., 23 sccm O2, 127 sccm Ar, 400 mTorr) at 100 W to 800 W, preferably about 400 W, for 1 to 10 minutes, particularly about 5 minutes per IOL side. Performance and duration can be varied as needed to achieve desired surface properties. In the plasma furnace, oxygen can be converted to ozone, which enhances the treatment. Alternatively or additionally, the ophthalmic lens is stored, preferably in a dehydrated state, in a storage cassette and / or in an implantation tool for implanting the lens into the eye. Alternatively or additionally, the lens of the present invention can be advantageously used in dry and optionally fully pre-filled injection systems, and need not be packaged or stored in a liquid. This simplifies packaging and significantly extends shelf life and handling.

[0042] Polymer biomaterials produced by polymerization of the ophthalmic composition according to the first aspect of the invention constitute another independent aspect of the invention. Thermally induced free radical polymerization is preferred here. Photochemically induced polymerization is also conceivable.

[0043] Another independent aspect of the invention is plasma treatment of ophthalmic lenses. This can advantageously reduce the surface tack of the lens without requiring chemical coatings (e.g., heparin in an impregnation process). Preferred procedures and parameters for plasma treatment should be derived from the above description of the second aspect of the invention.

[0044] Further features of the invention will become apparent from the claims and working examples. Without departing from the scope of the invention, the features and combinations of features mentioned above, as well as the features and combinations of features mentioned and / or shown individually in the following working examples, can be used not only in the correspondingly specified combinations, but also in other combinations or individually. Therefore, the invention should also be considered to include and disclose configurations that are not explicitly shown and illustrated in the working examples, but which are apparent from the illustrated configurations and can be created by individual combinations of features. The disclosure should also be considered to extend to combinations of embodiments and features that do not possess all the features of the independent claims as stated in the initial wording. Figure 1 A schematic diagram of an ophthalmic lens according to a working example of the present invention is shown. Detailed Implementation

[0045] Figure 1 A schematic diagram of an ophthalmic lens 10 according to a working example of the invention is shown. In this context, the ophthalmic lens 10 takes the form of a soft intraocular lens (IOL) and has a body 12. In this example, the body 12 has a first region 14a and a second region 14b, which differ in at least one parameter in the stiffness and hardness group. For this purpose, for example, regions 14a and 14b may be produced by different embodiments of the ophthalmic compositions discussed in detail below or undergo different post-treatments. However, in the simplest form, regions 14a and 14b are produced by the same ophthalmic composition and are not different at the molecular level. The IOL 10 in the illustrated exemplary embodiment has an optical portion 16 and a substantially optional tactile portion 18, which is wing-shaped in the present case. However, the geometry of the tactile portion 18 can be fundamentally altered and can take, for example, the form of a hook.

[0046] To produce IOL 10, the ophthalmic composition of the present invention is used, comprising comonomer groups A) to C), at least one of the comonomer groups D), E), or mixtures thereof, and at least one crosslinking agent F). In this context, A) represents at least one (meth)acrylate having at least one aromatic group; B) represents at least one (meth)acrylate having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; C) represents at least one (meth)acrylate having at least one hydroxyl group; D) represents at least one (meth)acrylamide having an aromatic group and having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; and E) represents at least one (meth)acrylamide having two aromatic groups and at least one (meth)acrylamide having two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups.

[0047] Comonomer groups A) through D) / E) are discussed in detail in Table 2 below, along with their meanings, illustrative compounds, and illustrative mass proportions based on the total weight of the composition. These mass proportions relate to the sum of all compounds in the corresponding categories A) through D) / E). For example, if category A) contains three different compounds and has a mass proportion of 50% by weight of the total weight of the composition, then this mass proportion is constituted by the sum of the individual mass proportions of the three compounds in category A).

[0048] Table 2: Comonomer groups A) to D) / E)

[0049]

[0050] Abbreviation meaning:

[0051] PEMA 2-phenylethyl methacrylate

[0052] PEA 2-Phenylethyl Acrylate

[0053] EGPEA (ethylene glycol phenyl ether acrylate)

[0054] nBuA Butyl Acrylate

[0055] iBuA Isobutyl Acrylate

[0056] EHA 2-Ethylhexyl Acrylate

[0057] HEMA 2-hydroxyethyl methacrylate

[0058] HEA 2-Hydroxyethyl Acrylate

[0059] HBA 4-hydroxybutyl acrylate

[0060] BIPA N-Benzyl-N-Isopropylacrylamide

[0061] BBA N-benzyl-N-butylacrylamide

[0062] BIBA N-Benzyl-N-Isobutylacrylamide

[0063] BIPEA N-Benzyl-N-Isopentylacrylamide

[0064] BMA N-benzyl-N-methylacrylamide

[0065] BHEA N-Benzyl-N-2-Hydroxyethylacrylamide

[0066] As already mentioned, acrylates and corresponding methacrylates, as well as acrylamides and corresponding methacrylamides, can generally be interchanged or mixed with each other. Within the scope of this disclosure, alkyl substituents can generally have 1 to 12 carbon atoms. For example, compounds having general formula III can generally be used as (meth)acrylamides:

[0067]

[0068] Wherein alkyl R 2 It can be unbranched or branched and unsubstituted, or particularly substituted with one, two, or more hydroxyl groups. When alkyl R 2 When substituted with one or more hydroxyl groups, preferably at least one hydroxyl group is at the terminal. Compounds having Formula III are preferably N-benzyl-N-isopropylacrylamide (BIPA):

[0069]

[0070] Compounds having formula III can be N-benzyl-N-isobutylacrylamide (BIBA):

[0071]

[0072] Compounds having Formula III can be N-benzyl-N-isopentylacrylamide (BIPEA):

[0073]

[0074] Compounds having formula III can be N-benzyl-N-2-hydroxyethylacrylamide (BHEA):

[0075]

[0076] In this case, ethyl R 2 The terminal hydroxyl groups are substituted, allowing compound BHEA to interact with comonomer C) as well as water molecules. Typically, two or more, for example two hydroxyl groups, can be provided as substituents, and thus compounds of group D) can conform to general formula IV, where n and m are chosen in the range of 1 to 10, such that the sum of n+m is in the range of 2 to 11.

[0077]

[0078] Instead of the acrylamide shown, as already mentioned, the corresponding methacrylamide and any mixture thereof can also be provided.

[0079] With reference to the corresponding illustrative compounds, the beneficial interactions of different comonomer groups A) to D) (or E)) are explained in detail in the following compositions V and VI.

[0080]

[0081] In composition V, for example, compounds EGPEA (comonomer type A), nBuA (comonomer type B), 2-HEMA (comonomer type C), and BBA (comonomer type D) are used. It can be seen that in composition V, favorable intermolecular interactions are formed due to the selected structural similarities of the individual comonomer types A) to D) (or similarly E)), as the mixed (meth)acrylamide D) acts as a mediator between groups A) and B). The aryl group of (meth)acrylamide D) also advantageously leads to an increase in refractive index and forms π-π interactions with the aryl group of aromatic monomer A), resulting in higher structural strength of the polymer. The alkyl group of (meth)acrylamide D) increases the flexibility of the material. On the other hand, comonomer type C can form hydrogen bonds with water molecules confined in the polymer and the amide groups of (meth)acrylamide D) / E) through its terminal and spatially unhindered hydroxyl groups.

[0082] The same considerations apply to composition VI, in which, for example, compounds PEA (comonomer type A), iBuA (comonomer type B), 2-HEMA (comonomer type C), and BIPA (comonomer type D) are used:

[0083]

[0084] Based on the material design strategy described above, for example, several novel ophthalmic compositions were produced, polymerized, and analyzed. The resulting polymeric biomaterials exhibited promising properties in terms of material flexibility and tensile strength, as well as a high refractive index. In addition to the introduced monomers, (2-(5-chloro-2H-benzotriazol-2-yl)-6-(1,1-dimethylethyl)-4-vinylphenol (UVAM) and 2,2'-azobis(2-methylpropionitrile) (AIBN), as UV blockers for ophthalmic materials, were used for thermal radical initiation of the compositions. Table 3 shows illustrative ophthalmic compositions (identified as "T-30C" and existing in the polymerized state as optically transparent biomaterials) with their respective compositional groups and amounts used.

[0085] Table 3: Ophthalmic Composition T-30C of the Invention

[0086]

[0087] However, this ophthalmic composition is not only suitable for producing transparent ophthalmic biomaterials. By adding an appropriate amount (typically <1.0% by weight) of a yellow dye (Group H), this ophthalmic composition can be readily adapted to produce yellow biomaterials. The amount of yellow dye used in this composition can be selected within a wide concentration range as needed. In this example, it was adjusted so that the composition has the same optical properties as the commercially available yellow biomaterial ZEISS CT Lucia (Acrylmex Y) in terms of the percentage of transmission at each wavelength in the 400 nm to 500 nm range. This is achieved by adding a small amount (<1.0% by weight) of the blue-absorbing yellow dye 4-(3-vinylphenylazo)diphenylamine (3VPADPA or VPAD) to the composition "T-30C" shown above. The correspondingly adjusted composition is referred to below as "T-30Y".

[0088] Measurements from three batches of transparent (T-30C) and three batches of yellow (T-30Y) biomaterials were used to determine the average physical properties of each. Table 4 provides an overview of the average properties of the preferred transparent T-30C biomaterial for ophthalmic compositions, and Table 5 provides an overview of the average properties of the preferred yellow T-30Y biomaterial for ophthalmic compositions.

[0089] Table 4: Properties of T-30C, an optically transparent material

[0090]

[0091]

[0092] Table 5: Properties of Yellow Material T-30Y

[0093]

[0094] In addition to the properties highlighted in Tables 4 and 5, biomaterials also exhibit excellent anti-sparkling properties. The type and amount of crosslinking agent used in the elastomer affects mechanical properties and can also be used to reduce sparkling. However, even in the case of compositions known from the prior art, variations in the amount of crosslinking agent alone are insufficient to achieve all the aforementioned requirements for the material, including the reduction of sparkling. However, it has been found that even with a constant amount of crosslinking agent (e.g., about 3% by weight), the addition of (meth)acrylamide comonomers (D) / E) helps to orient the material properties in the desired direction.

[0095] Compared to low-sparkle hydrophilic compositions known from the prior art that must be stored in saline solutions, the ophthalmic compositions of the present invention offer both the possibility of dry storage and the possibility of steam sterilization. The water-absorbing properties of the tailored polymeric biomaterials allow these conflicting requirements to be met using only a single material.

[0096] To confirm this experimentally, a flare study was conducted. Five IOLs, each with a refractive power of 20.0D, were produced from the ophthalmic composition of this invention during accelerated aging and stored in a 0.9% sodium chloride solution at 45°C for 24 hours. The lenses were then incubated at 37°C for 2.5 hours and examined under a microscope using a digital camera and vacuolation detection software (Image J). Two of the five IOLs were found to remain completely free of microvacuoles (MV) during the accelerated aging process. The other three IOLs had a MV / mm² value of approximately 0.61. 2 The microbubble count is extremely low. This density not only corresponds to level 0 on the Miyata scale, but is also far below the MV density achievable by most currently commercially available IOL models in previous studies. The results of these previous studies are summarized in Table 6.

[0097] Table 6: Summary of the scintillation study results for various IOL models

[0098]

[0099] Based on the test results, the material composition T-30C can be described not only as flicker-free but also as suitable for producing microvacuole-free lenses. It is important to note that the preferred ophthalmic compositions described in Table 3 can be adjusted for the compounds used in each comonomer group and for the concentration range of each comonomer group. Therefore, many alternative formulations of the compositions are possible within the scope of this disclosure, and these formulations also possess the advantageous properties of the materials of this invention.

[0100] It has been found that biomaterials produced from the compositions of the present invention, having a water absorption capacity of about 1.8% by weight, result in sufficient water distribution within the polymer to prevent scintillation. Simultaneously, the water content is low enough not to cause problems due to swelling of the lens after implantation, and therefore storage in an aqueous environment is unnecessary. Furthermore, the water content and chemical composition allow for vapor sterilization of the lens.

[0101] It was determined that a lens with a 5mm optical zone (made of the materials of the present invention, such as T-30C or T-30Y) can be injected without significant force consumption using a Medicel Accuject syringe with a 1.8mm cartridge. This meets the requirements for cataract surgery with micro-incisions. The IOL of the present invention can also be injected without difficulty using an Accuject 2.2 cartridge. In vitro injection tests were conducted using OVD (Ophthalmic Viscoelastic Device) or saline solution (BSS). The suitability arises from both the high refractive index of the materials of the present invention (which requires a lower lens thickness) and their flexibility (which is strongly influenced by the low glass transition temperature (Tg) of the material). The latter should be designed very carefully, as too high a Tg may harden the polymer and too low a Tg may make machining more difficult. The compositions of the present invention, T-30C / T-30Y, have a Tg of about 6°C and are therefore at the lower limit of the range of hydrophobic acrylate-based IOL materials (see Table 1). In addition to the production of the lens, mechanical tests were conducted to demonstrate the machinability of the biomaterials produced from the compositions of the present invention.

[0102] Furthermore, the T-30C biomaterial was characterized by dynamic-mechanical thermal analysis (DMTA). To simulate the conditions during cryogenic turning and cryogenic milling of the material, the average rotational speeds of turning (7500 rpm = 125 Hz) and milling (14000 rpm = 233 Hz) were used as the load frequencies. Following experimental analysis, the shear storage modulus G' and shear loss modulus G' were determined. Several different non-covalent bonds can be formed between the functional polymer groups of the compositions of the present invention (see compositions V and VI). These forces can be overcome when the biomaterial is heated (e.g., during steam sterilization) and regenerate automatically when the material is cooled. DMTA testing showed that Tg changed by only about 2 K when the load frequency was doubled, resulting in good stability throughout the machining process. Furthermore, the biomaterial of the present invention exhibits a significantly smaller decrease in material stiffness (shear storage modulus G') with increasing temperature in the glassy state. Therefore, when the biomaterial of the present invention is machined (e.g., at -20°C), it thus possesses higher stiffness. At room temperature or higher, T-30C / Y is significantly softer, as already mentioned, which leads to better implantability.

[0103] In addition to the advantages already highlighted, the biomaterial of this invention was tested against standard requirements for ophthalmic lenses. These tests included photostability studies, including UV stability of the biomaterial and extraction from storage solutions. These tests were also successfully completed. Furthermore, several biocompatibility tests were conducted, including cytotoxicity studies and risk analyses, which were also successfully completed. Material adhesion tests were also performed, which is particularly important because the biomaterial of this invention has low Tg and high flexibility. For this purpose, the biomaterial disc of this invention was cut to a smooth surface and pushed together with a certain force, and the force required for separation was then measured. Combined with additional injection tests, it was found that no chemical coating (e.g., heparin during impregnation) is required for this biomaterial, and a simple plasma treatment specifically developed for this purpose is sufficient to reduce surface adhesion. This plasma treatment process has also proven to be stable over a long period of more than one year, thus ensuring the safe unfolding of the lens after the storage period. The plasma treatment was performed in a furnace equipped with an RF plasma generator (13.56 MHz) at 400 W in a mixed atmosphere of oxygen and argon (23 sccm O2, 127 sccm Ar, 400 mTorr) for 5 minutes per IOL side. In the plasma furnace, oxygen was converted to ozone, which enhanced the treatment.

[0104] Finally, the suitability of the biomaterials of the present invention for steam sterilization was tested. For these tests, discs with a thickness of 1.0 mm and a diameter of 6.0 mm were produced by low-temperature rotation from the biomaterials and several hydrophobic acrylate materials known in the art. The discs were hydrated in an appropriate amount of aqueous solution in an autoclave at room temperature for 48 hours. All containers were transferred to an autoclave and heated to 121°C at a standard rate (+6.6 K / min, for a total of 15 min). The containers were held at this temperature for 30 minutes before being gradually cooled to room temperature (21°C). Cooling should preferably be carried out at the slowest possible rate (e.g., -0.07 K / min, for a total of 24 h). Visible defects in these panels were then examined, particularly microvacuoles formed within the material. In the tests conducted, the discs with the T-30C composition did not show permanent damage due to microvacuoles and were able to outperform the hydrophobic reference samples in this respect. Therefore, the biomaterials and lenses of the present invention are suitable for steam sterilization.

[0105] Table 7 below reports further working examples of the ophthalmic compositions of the present invention. The biomaterials and lenses produced therefrom possess the same advantageous properties as the material T-30C / Y already discussed. The alternative compositions reported in Table 7 follow the described strategy and, by way of example and non-exhaustive demonstration, show which changes are possible to obtain comparable optical, physical, and mechanical properties of the corresponding biomaterials by exchanging comonomers and / or by varying the proportions of the groups used.

[0106] Table 7: Working Examples of the Ophthalmic Compositions of the Invention

[0107]

[0108] The parameter values ​​specified in the literature for defining the specific characteristics of the subject matter of the present invention for the purpose of characterizing the subject matter should also be considered to be covered within the scope of the present invention in the case of deviations caused, for example, by measurement error, systematic error, weighing error, DIN tolerance, etc.

[0109] List of reference numerals 10. Lens (IOL) 12. Main body

[0110] 14a First Region

[0111] 14b Second Region

[0112] 16 Optical components 18 Tactile components

Claims

1. An ophthalmic composition for producing an ophthalmic lens (10), the ophthalmic composition comprising a comonomer group A) to C), at least one of a comonomer group D), E), or a mixture thereof, and at least one crosslinking agent F), wherein, - A) indicates at least one (meth)acrylate having at least one aromatic group; - B) indicates at least one (meth)acrylate having an open-chain aliphatic group; - C) indicates at least one (meth)acrylate having at least one hydroxyl group; - D) represents at least one (meth)acrylamide having an aromatic group and an alkyl group; and - E) represents a mixture of at least one (meth)acrylamide having two aromatic groups and at least one (meth)acrylamide having two alkyl groups; Its features are, Based on the total weight of the ophthalmic composition - The proportion of comonomer group A) is between 39% and 50% by weight; - The proportion of comonomer group B) is between 10% and 45% by weight; - The proportion of comonomer group C) is between 5% and 30% by weight; - The total proportion of comonomer groups D) and E) is between 1% and 14% by weight; and - The proportion of the crosslinking agent F) is no more than 5% by weight.

2. The ophthalmic composition as described in claim 1, Its features are, - A) Including 2-phenylethyl (meth)acrylate, ethylene glycol phenyl ether (meth)acrylate, or mixtures thereof; and / or - B) Including butyl (meth)acrylate, isobutyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, or mixtures thereof; and / or - C) Including 2-hydroxyethyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate, or mixtures thereof; and / or - D) Including N-benzyl-N-isopropyl(meth)acrylamide, N-benzyl-N-butyl(meth)acrylamide, N-benzyl-N-isobutyl(meth)acrylamide, N-benzyl-N-isopentyl(meth)acrylamide, N-benzyl-N-pentyl(meth)acrylamide, N-benzyl-N-methyl(meth)acrylamide, or mixtures thereof; and / or - E) Includes N,N-dibenzyl (meth)acrylamide and N,N-diisopropyl (meth)acrylamide, N,N-dibenzyl (meth)acrylamide and N,N-dibutyl (meth)acrylamide, N,N-dibenzyl (meth)acrylamide and N,N-diisobutyl (meth)acrylamide, N,N-dibenzyl (meth)acrylamide, N,N-diisopentyl (meth)acrylamide and N,N-dipentyl (meth)acrylamide, N,N-dibenzyl (meth)acrylamide and N,N-dimethyl (meth)acrylamide or mixtures thereof; and / or - F) Includes crosslinking agents having at least two (meth)acrylate groups.

3. The ophthalmic composition as described in claim 1 or 2, Its features are, It contains at least one additional component G), H), I), or a mixture thereof, wherein, - G) indicates at least one UV absorber; - H) represents at least one dye used to modify light absorption properties; and - I) indicates polymerization initiator.

4. The ophthalmic composition as described in claim 3, Its features are, Based on the total weight of the ophthalmic composition - The proportion of component G) is no more than 2% by weight; and / or - The proportion of component H) is no more than 5% by weight; and / or - The proportion of component I) is no more than 3% by weight.

5. The ophthalmic composition as described in claim 3, Its features are, The UV absorber G) includes 2-(5-chloro-2H-benzotriazol-2-yl)-6-(1,1-dimethylethyl)-4-vinylphenol, and / or the dye H) includes 4-(3-vinylphenylazo)diphenylamine.

6. An ophthalmic lens (10), at least partially produced from the ophthalmic composition as claimed in any one of claims 1 to 5.

7. The ophthalmic lens (10) as described in claim 6, Its features are, The ophthalmic lens - Has a refractive index n in the non-hydrated state D,20°C > 1.51; and / or - Has a refractive index n in the hydrated state D,35°C > 1.50; and / or - Having a Shore A hardness of less than 80 (t = 3 s) and / or a Shore A hardness of less than 50 (t = 10 min); and / or - Has a glass transition temperature between 0°C and 15°C; and / or - Possesses water absorption capacity between 0.5% and 3.5% by weight at 35°C; and / or - Has an Abbe number of at least 30.

8. The ophthalmic lens (10) as described in claim 6 or 7, Its features are, In an in vitro scintillation test performed by accelerated aging, wherein the lens (10) was first placed in a saline solution at 45°C ± 1°C for 24 h and then at 37°C ± 1°C for 2.5 h, the ophthalmic lens exhibited a scintillation rate not exceeding 10 MVs / mm. 2 The density of microbubbles.

9. The ophthalmic lens (10) as described in claim 6 or 7, Its features are, The ophthalmic lens has been steam sterilized and / or treated with plasma, and / or Stored in a dehydrated state in a storage box and / or in an implantation tool for implanting the lens (10) into the eye.

Images